FrancophonIA/ELRC3.0 huggingface dataset:
English: <1/1,000) or very rare (<1/10,000) cannot be estimated from the available data.
Danish: Ikke almindelig (≥1/1.000 til <1/100), sjælden (≥1/10.000 til <1/1.000) eller meget sjælden (<1/10.000) hyppighed kan ikke estimeres ud fra forhåndenværende data.
English: Factor X is an inactive zymogen, which can be activated by factor IXa (via the intrinsic pathway) or by factor VIIa (via the extrinsic pathway).
Danish: Faktor X er et inaktivt forstadie (zymogen), som kan aktiveres af faktor IXa (ad den indre aktiveringsvej) eller af faktor VIIa (ad den ydre aktiveringsvej).
English: This medicinal product contains up to 0.4 mmol/mL (9.2 mg/mL) of sodium.
Danish: Dette lægemiddel indeholder op til 0,4 mmol/ml (9,2 mg/ml) natrium.
English: The formation of neutralising antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency.
Danish: Dannelsen af neutraliserende antistoffer (inhibitorer) til faktor X er en mulig komplikation i behandlingen af personer med faktor X-mangel.
English: Due to the rarity of hereditary factor X deficiency, experience regarding the use of Coagadex during pregnancy and breast-feeding is not available.
Danish: Idet arvelig faktor X-mangel sjældent forekommer, foreligger der ingen erfaringer med brugen af Coagadex under graviditet og amning.
English: The other two subjects used doses up to 30 IU/kg and 33 IU/kg.
Danish: De to andre forsøgsdeltagere benyttede doser op til 30 IE/kg og 33 IE/kg.
English: Patients with factor X deficiency do not have sufficient factor X for their blood to clot properly, leading to excessive bleeding.
Danish: Patienter med faktor X-mangel har ikke tilstrækkelig faktor X i deres blod til, at det kan størkne rigtigt, hvilket fører til overdrevet blødning.
English: Systemic exposure to FX:C at the Repeat PK visit (at least 6 months later) was equivalent to that at baseline, since repeat/baseline ratios for all PK parameters were within the range of 90% to 110%.
Danish: Systemisk eksponering over for FX:C ved gentagne PK-besøg (mindst 6 måneder senere) svarede til det ved baseline, da gentagne/baseline-nøgletal for alle farmakokinetiske parametre lå inden for intervallet 90 % til 110 %.
English: The product should only be reconstituted using the Mix2Vial that is provided in the pack.
Danish: Produktet må kun restitueres med Mix2Vial, som leveres med pakningen.
English: Your medicine must only be dissolved in the solvent provided with the product.
Danish: Medicinen må kun opløses i opløsningsmidlet, som leveres sammen med produktet.
English: Talk to your doctor, pharmacist or nurse before using Coagadex:
Danish: Kontakt lægen, apotekspersonalet eller sundhedspersonalet før du tager Coagadex:
English: Trough levels of FX:C were measured during the first 6 weeks of the study to individualise the dosage regimen and to maintain a trough level of at least 5 IU/dL.
Danish: Minimumsniveauer af FX:C blev målt i løbet af de første 6 uger af studiet for at individualisere doseringsprogrammet og for at opretholde et minimumsniveau på mindst 5 IE/dl.
English: A dose of 2000 IU Coagadex administered to a 70 kg patient should be expected to result in a peak post-infusion factor X increase of 2000 x {[2 IU/dL]/[IU/kg]}/[70 kg] = 57 IU/dL (i.e. 57% of normal)
Danish: En dosis på 2000 IE Coagadex administreret til en patient på 70 kg kan forventes at resultere i en peak post-infusionsfaktor X-stigning på 2000 x {[2 IE/dl]/[IE/kg]}/[70 kg] = 57 IE/dl (dvs. 57 % af det normale)
English: Coagadex is likely to be counteracted by factor Xa inhibitors, direct or indirect.
Danish: Coagadex modvirkes sandsynligvis af faktor Xa-inhibitorer, direkte eller indirekte.
English: Pharmacotherapeutic group: Anti-haemorrhagics, vitamin K and other haemostatics, coagulation factor X, ATC code: B02BD13.
Danish: Farmakoterapeutisk klassifikation: Anti-hæmoragiske midler, K-vitamin og andre hæmostatiske midler, koagulationsfaktor X, ATC-kode: B02BD13.
English: Example: to raise plasma factor X level from 15 IU/dL to 90 IU/dL in a 70 kg patient, the appropriate dose is:
Danish: Eksempel: For at hæve plasma faktor X-niveauet fra 15 IE/dl til 90 IE/dl hos en patient, der vejer 70 kg, er den passende dosis:
English: The powder should only be reconstituted with the water for injections provided in the pack.
Danish: Pulveret må kun restitueres med vandet til injektionsvæske, som er vedlagt i pakningen.
English: One case of accidental overdose was reported in the clinical trials, in which a subject received approximately 80 IU/kg Coagadex to treat a bleed.
Danish: Der blev indberettet et enkelt tilfælde af utilsigtet overdosis i de kliniske forsøg, hvor en patient modtog ca. 80 IE/kg Coagadex til behandling af en blødning.
English: These antithrombotic agents should not be used in patients with factor X deficiency.
Danish: Disse antitrombotiske midler bør ikke anvendes til patienter med faktor X-mangel.
English: If expected factor X activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor X inhibitor concentration.
Danish: Hvis de forventede faktor Xaktivitetsniveauer ikke opnås, eller hvis blødning ikke kan kontrolleres med en forventet dosis, skal der udføres en analyse, der måler faktor X-inhibitorkoncentrationen.
English: All were treated with a single infusion of Coagadex; mean and median doses 31.7 IU/kg (range 24.6 to 38.8 IU/kg) and all recorded efficacy ratings were categorized as excellent.
Danish: Alle blev behandlet med en enkelt infusion af Coagadex (gennemsnitlige og mediane doser på 31,7 IE/kg, interval fra 24,6 til 38,8 IE/kg), og alle registrerede virkningsklassifikationer blev kategoriseret som fremragende.
English: Before: The dose of Coagadex used should be sufficient to raise your blood factor X level to between 70 and 90 units/dL.
Danish: Før: Den dosis Coagadex, der anvendes, bør være tilstrækkelig til at hæve blodets faktor X-niveau til mellem 70 og 90 enheder/dl.
English: Certain anticoagulants including those blocking a blood clotting factor (factor Xa) should not be used in patients with factor X deficiency receiving Coagadex due to a risk of blood clots.
Danish: Visse antikoagulanter, inklusive dem, som blokerer en blodstørknende faktor (faktor Xa) må ikke gives til patienter med faktor X-mangel, som får Coagadex, grundet risiko for blodpropper.
English: 25 IU/kg twice weekly is the proposed starting dose for prophylaxis in patients >12 years of age with dose levels and dosing intervals to be adjusted as clinically indicated.
Danish: 25 IE/kg to gange ugentligt er den foreslåede startdosis for profylakse hos patienter >12 år, hvor dosisniveauer og doseringsintervaller kan blive justeret efter klinisk indikation.
English: The safety and efficacy of Coagadex for perioperative management was evaluated in five subjects aged 14 to 59 years with mild (n=2), moderate (n=1), and severe (n=2) disease, who underwent a total of seven surgical procedures.
Danish: Sikkerheden og effekten af Coagadex til perioperativ behandling blev evalueret i fem forsøgsdeltagere i alderen 14 til 59 år med mild (n=2), moderat (n=1) og svær (n=2) sygdom, der fik foretaget i alt syv kirurgiske procedurer.
English: It is used to treat and prevent bleeding in patients with hereditary factor X deficiency, including during surgery.
Danish: Det anvendes til at behandle og forebygge blødninger hos patienter med arvelig faktor X-mangel, bl.a. under operation.
English: Pharmacokinetic (PK) parameters were calculated from plasma factor X:C (one-stage clotting assay) activity measurements after subtraction of the pre-dose value.
Danish: Farmakokinetiske (PK) parametre blev beregnet fra plasma faktor X:C (1-trins koagulationsanalyse) aktivitetsmålinger efter subtraktion af præ-dosis værdien.
English: The mean (CV%) for incremental recovery was 2.08 (18.1).
Danish: Gennemsnittet (CV %) for gradvis bedring som 2,08 (18,1).
English: Coagadex is a concentrate of human coagulation factor X, a protein that is needed for blood to clot.
Danish: Coagadex er et koncentrat af human koagulationsfaktor X - et protein, der kræves for at blod kan størkne.
English: The mean (CV%) maximum plasma concentration (Cmax) was 0.504 (17.2) IU/mL.
Danish: Gennemsnittet (CV %) for maksimal plasmakoncentration (Cmax) var 0,504 (17,2) IE/ml.
English: Coagadex should be injected directly into a vein.
Danish: Coagadex skal injiceres direkte ind i en blodåre.
English: Similarly, combining t½ values at the Baseline Visit and the Repeat PK assessment gave an overall geometric mean t½ of 29.36 hours.
Danish: Ligeledes gav de kombinerede t½-værdier ved baselinebesøget og den gentagne PK-vurdering en samlet t½ geometrik på 29,36 timer.
English: Coagadex replaces the missing factor X and allows their blood to clot normally.
Danish: Coagadex erstatter den manglende faktor X og gør, at blodet størkner normalt.
English: Routine prophylaxis was started with unit doses of 40-50 IU/kg and during the first 6 weeks trough levels of Factor X were measured to adjust the dosage regimen to maintain a trough level of at least 5 IU/dL.
Danish: Rutinemæssig profylakse blev startet med enhedsdoser på 40-50 IE/kg, og i de første 6 uger blev minimumsniveauer af faktor X målt for at justere doseringsprogrammet for at opretholde et minimumsniveau på mindst 5 IE/dl.
English: Coagadex contains up to 0.4 mmol/mL (9.2 mg/mL) of sodium.
Danish: Coagadex indeholder op til 0,4 mmol/ml (9,2 mg/ml) natrium.
English: There is a potential for thromboembolism with overdose.
Danish: Overdosis er forbundet med risiko for tromboembolisme.
English: This should be taken into consideration by patients on a controlled sodium diet.
Danish: Dette skal tages med ind i overvejelserne ved patienter, som er på natriumfattig kost.
English: Median and mean doses per infusion in the four children less than 6 years of age were both 40.1 IU/kg (95% CI 30.70, 49.57) and in the five children 6 to 11 years of age inclusive, median dose was 39.6 IU/kg and mean dose was 37.7 IU/kg (95% CI: 23.42, 51.91).
Danish: Mediane og gennemsnitlige doser pr. infusion hos de 4 børn under 6 år var begge 40,1 IE/kg (95 % CI 30,70; 49,57), og hos de 5 børn fra 6 til og med 11 år var mediandosis 39,6 IE/kg, og den gennemsnitlige dosis var 37,7 IE/kg (95 % CI: 23,42; 51,91).
English: If you know you have used too much, tell the doctor, pharmacist or nurse as soon as possible.
Danish: Hvis du ved, at du har taget for meget, skal du fortælle det til lægen, apotekspersonalet eller sundhedspersonalet så hurtigt som muligt.
English: List of adverse reactions (ADRs) in 27 treated subjects MedDRA System Organ Class
Danish: Liste over bivirkninger hos 27 behandlede forsøgsdeltagere Systemorganklasser i henhold til MedDRAdatabasen
English: Powder vial containing white or off-white powder.
Danish: Pulverhætteglas indeholder hvidt eller råhvidt pulver.
English: - if you are allergic to human coagulation factor X or any of the other ingredients of this medicine
Danish: - hvis du er allergisk over for human koagulationsfaktor X eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet i afsnit 6).
English: • Draw air into the syringe by pulling the plunger to the required volume of water added.
Danish: • Træk luft ind i sprøjten ved at trække stemplet til den krævede mængde vand, der er tilsat.
English: If you think you may be using too much, stop the injection and tell the doctor, pharmacist or nurse.
Danish: Hvis du mener, at du tager for meget, skal du stoppe injektionen og fortælle det til lægen, apotekspersonalet eller sundhedspersonalet.
English: The expected in vivo peak increase in factor X level expressed as IU/dL (or % of normal) can be estimated using the following formulae:
Danish: Den forventede in vivo maksimale stigning i faktor X-niveauet, udtrykt som IE/dl (eller % af normalen) kan estimeres ved hjælp af den følgende formel:
English: Repeat this step with the solvent vial.
Danish: Gentag dette trin med hætteglasset med opløsningsmidlet.
English: The mean (CV%) for area under the curve (AUC 0-144h) was 17.1 (21.0) IU.hr/mL.
Danish: Gennemsnittet (CV %) for området under kurven (AUC 0-144h) var 17,1 (21,0) IE.time/ml.
English: Frequencies have been evaluated according to the following convention: very common (≥1/10 subjects); common (≥1/100 to <1/10).
Danish: Hyppighed i henhold til MedDRA-konventionen: Meget almindelig (≥1/10); almindelig
English: The 250 IU and 500 IU presentations should be reconstituted using 2.5 mL and 5 mL water for injections, respectively.
Danish: 250 IE og 500 IE-præsentationerne skal restitueres med hhv. 2,5 ml og 5 ml vand til injektionsvæske.
English: The mean (CV%) half-life of human coagulation factor X was 30.3 (22.8) hr and clearance was 1.35 (21.7) mL/kg/hr.
Danish: Gennemsnittet (CV %) for halveringstiden for human koagulationsfaktor X var 30,3 (22,8) time og clearance var 1,35 (21,7) ml/kg/time.
English: In adults and adolescents at least 12 years of age, the expected in vivo peak increase in factor X level expressed as IU/dL (or % of normal) can be estimated using the following formulae:
Danish: Hos voksne og unge, der er mindst 12 år, kan den forventede in vivo-peak-stigning i faktor X-niveau udtrykt som IE/dl (eller % af det normale) estimeres ved hjælp af følgende formler:
English: 1 transfer device
Danish: 1 overførselsenhed
English: Coagadex is derived from human plasma and used as a replacement for the naturally existing coagulation factor X in patients with hereditary factor X deficiency.
Danish: Coagadex er afledt af humant plasma og anvendes som en erstatning for den naturligt eksisterende koagulationsfaktor X hos patienter med arvelig faktor X-mangel.
English: Some patients with a shortage of factor X may develop inhibitors (antibodies) to factor X during treatment.
Danish: Nogle patienter med faktor X-mangel kan udvikle hæmmere (immunstoffer) over for faktor X under behandling.
English: What you need to know before you use Coagadex Do not use Coagadex:
Danish: Det skal du vide, før du begynder at bruge Coagadex Brug ikke Coagadex:
English: In a clinical study of Coagadex in subjects with severe or moderate factor X deficiency (basal FX:C <5 IU/dL), the pharmacokinetics of Coagadex were assessed in 16 subjects after administration of a nominal dose of 25 IU/kg.
Danish: I en klinisk undersøgelse af Coagadex hos patienter med svær eller moderat faktor X-mangel (basal FX:C <5 IE/dl), blev Coagadex' farmakokinetik vurderet hos 16 forsøgsdeltagere efter administration af en nominel dosis på 25 IE/kg.
English: The adverse reactions that occurred in the highest frequency were infusion site erythema, infusion site pain, fatigue, and back pain.
Danish: De bivirkninger, der opstod med højeste hyppighed, var rødmen og smerter omkring infusionsstedet samt træthed og rygsmerter.
English: • Gently swirl the vial to make sure the powder is thoroughly mixed.
Danish: • Bevæg forsigtigt glasset rundt for at sikre, at pulveret blandes godt.
English: Coagadex is supplied with the amount of solvent as shown in the table.
Danish: Coagadex leveres med den mængde opløsningsmiddel, der er vist i tabellen.
English: For on-demand control of bleeding in children aged less than 12 years: 30 IU/kg Coagadex should be injected when the first sign of bleeding occurs.
Danish: Til blødningskontrol efter behov hos børn under 12 år: 30 IE/kg Coagadex skal injiceres, når det første blødningstegn opstår.
English: Once made up, Coagadex must be used within one hour.
Danish: Når er blandet, skal det benyttes inden for en time.
English: Adjust dosage regimen to clinical response and trough levels of Factor X of at least 5 IU/dL.
Danish: Juster doseringsprogrammet til klinisk respons og minimumsniveauer af faktor X på mindst 5 IE/dL
English: Hypersensitivity reactions, allergic reactions, and anaphylaxis have not been reported in Coagadex clinical trials.
Danish: Overfølsomhedsreaktioner, allergiske reaktioner og anafylaksi er ikke blevet indberettet i kliniske forsøg med Coagadex.
English: Coagadex contains sodium
Danish: Coagadex indeholder natrium
English: It is strongly recommended that every time that Coagadex is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.
Danish: Det anbefales på det kraftigste, at produktets navn og batchnummer registreres, hver gang Coagadex administreres til en patient, for at kunne knytte patienten til produktbatchen.
English: In a multicentre, open-label, non-randomised clinical trial to evaluate the pharmacokinetics, safety and efficacy of Coagadex, 16 subjects (aged 12 years and above) with moderate to severe hereditary factor X deficiency (FX:C < 5 IU/dL) received a dose of 25 IU/kg Coagadex to treat spontaneous, traumatic and menorrhagic bleeding episodes.
Danish: I et multicenter, ikke-blindet, ikke-randomiseret klinisk forsøg for at vurdere farmakokinetik, sikkerhed og virkning af Coagadex, fik 16 forsøgsdeltagere (i alderen 12 år og derover) med moderat til svær arvelig faktor X-mangel (FX: C <5 IE/dl ) en dosis på 25 IE/kg Coagadex til behandling af spontane, traumatiske og kraftige blødningsepisoder.
English: After being made up, the solution is colourless, clear or pearl-like (opalescent).
Danish: Efter blanding er opløsningsmidlet gennemsigtigt eller perleagtigt (opaliserende).
English: Gently swirl the vial to make sure the powder is thoroughly mixed.
Danish: Vend forsigtigt hætteglasset for at sikre, at pulveret blandes godt.
English: Before injection, look at the solution.
Danish: Se på opløsningen før injektion.
English: Coagadex should not be used as an antidote to the effects of direct oral anti-coagulants (DOACs) in patients who do not have factor X deficiency.
Danish: Coagadex bør ikke bruges som modgift mod effekten af direkte orale antikoagulerende lægemidler hos patienter, der ikke har faktor X-mangel.
English: Remove the plastic outer packaging from the transfer device and discard it, taking care not to touch the exposed end of the device.
Danish: Fjern den ydre plastikemballage fra overførselsenheden, kassér den og pas på ikke at berøre den eksponerede ende af enheden.
English: A transfer device called Mix2Vial is also provided.
Danish: Der medfølger desuden en overførselsenhed, Mix2Vial.
English: For the subgroup aged 6-11 years (n=5), the geometric mean IR30min was 1.91 (range 1.6 -2.2) IU/mL per IU/kg and for the youngest subgroup, 0-5 years (n=4) was 1.53range 1.3-1.8) IU/mL per IU/kg.
Danish: For undergruppen i alderen 6-11 år (n=5) var det geometriske gennemsnit IR30min 1,91 (interval 1,6-2,2) IE/ml pr. IE/kg, og for den yngste undergruppe fra 0-5 år (n=4) var det (interval 1,3-1,8) IE/ml pr. IE/kg.
English: Perioperative Management (Adults and adolescents aged at least 12 years of age) Pre-surgery: calculate dose of Coagadex to raise plasma factor X levels to 70-90 IU/dL.
Danish: Perioperativ behandling (voksne og unge på mindst 12 år) Præ-operativt: Beregn Coagadex-dosis for at hæve plasma faktor X-niveauerne til 70-90 IE/dl.
English: It is strongly recommended that every time you receive a dose of Coagadex, the name and batch number of the product are recorded in order to maintain a record of the batches used.
Danish: Det anbefales på det kraftigste, at produktets navn og batchnummer registreres, hver gang du får en dosis Coagadex®, for at føre regnskab med hvilke batch der er brugt.
English: Combining IR values for FX:C at the baseline visit (n=16) and the Repeat PK assessment (n=15) gave an overall geometric mean IR of 2.07 IU/dL per IU/kg administered (n=31).
Danish: Ved kombination af IR-værdierne for FX:C ved baselinebesøget (n=16) og gentagen PK-analyse (n=15) gav en generel gennemsnitlig geometrisk IR på 2,07 IE/kg administreret (n=31).
English: Fertility Animal reproduction studies have not been conducted with Coagadex.
Danish: Fertilitet Der er ikke gennemført reproduktionsforsøg med dyr med Coagadex.
English: Sodium hydroxide (for pH adjustment) Disodium phosphate dihydrate Sodium chloride
Danish: Natriumhydroxid (for pH-justering) Dinatriumphosphatdihydrat Natriumklorid
English: The median prophylactic dose per infusion per subject was 39.60 IU/kg (mean 38.76 IU/kg), and ranged from 18.0 to 47.3 IU/kg.
Danish: Den mediane profylaktiske dosis pr. infusion pr. person var 39,60 IE/kg (gennemsnit 38,76 IE/kg) og varierede fra 18,0 til 47,3 IE/kg.
English: Adults and adolescents aged 12 years or more for treatment of bleeding episodes: 25 IU/kg Coagadex should be injected when the first sign of bleeding occurs or just before the expected onset of menstrual bleeding.
Danish: Voksne og unge i alderen 12 år og derover til behandling af blødningsepisoder: Der skal injiceres 25 IE/kg Coagadex ved første tegn på blødning eller lige før forventet menstruation.
English: • Remove the plastic outer packaging from the transfer device and discard it, taking care not to touch the exposed end of the device.
Danish: • Fjern den ydre plastikemballage fra overførselsenheden kassér den og pas på ikke at berøre den eksponerede ende af enheden.
English: Coagadex contains traces of human proteins other than factor X. Patients should be informed of the early signs of hypersensitivity reactions including angioedema, infusion site inflammation (e.g. burning, stinging, erythema), chills, cough, dizziness, fever, flushing, generalised urticaria, headache, hives, hypotension, lethargy, musculoskeletal pains, nausea, pruritus, rash, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing.
Danish: Coagadex indeholder spor af andre humane proteiner end faktor X. Patienter skal informeres om tidlige tegn på overfølsomhedsreaktioner, herunder angioødem, inflammation omkring infusionsstedet (f.eks. brændende eller sviende fornemmelse eller rødmen), kulderystelser, hoste, svimmelhed, feber, rødmen, generaliseret urticaria, hovedpine, nældefeber, lavt blodtryk, sløvhed, smerter i knogler, led og muskler, kvalme, kløe, udslæt, rastløshed, takykardi, trykken for brystet, snurren, opkastning, hvæsen.
English: Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency.
Danish: Coagadex er indiceret til behandling og profylakse af blødningsepisoder og til perioperativ behandling hos patienter med arvelig faktor X-mangel.
English: • Repeat this step with the vial of solvent.
Danish: • Gentag dette trin med hætteglasset med opløsningsmidlet.
English: Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed rarely with treatment of other haemophilias and may in some cases have progressed to severe anaphylaxis (including shock).
Danish: Overfølsomhed eller allergiske reaktioner (som kan omfatte angioødem, brænden og svien omkring infusionsstedet, kulderystelser, rødmen, generaliseret urticaria, hovedpine, nældefeber, lavt blodtryk, sløvhed, kvalme, rastløshed, takykardi, trykken for brystet, prikken, opkastning, hiven efter vejret) er sjældent blevet observeret med behandling af anden hæmofili og kan i nogle tilfælde have udviklet sig til alvorlig anafylaksi (herunder chok).
English: Also contains: Powder vial: citric acid, sodium hydroxide, disodium phosphate dihydrate, sodium chloride, sucrose.
Danish: Indeholder også: Pulverhætteglas: citronsyre, natriumhydroxid, dinatriumfosfatdihydrat, natriumklorid, sakkarose
English: Signs of these may include skin rash (including hives), tingling, flushing, nausea, vomiting, headache, cough, wheezing, tightness of the chest, chills, fast heart rate, dizziness, lethargy, restlessness, swelling of the face, tightness of the throat, discomfort at the site of injection.
Danish: Tegn på disse kan omfatte udslæt (herunder nældefeber), prikken, rødmen, kvalme, opkastning, hovedpine, hoste, hvæsen, trykken for brystet, kulderystelser, hurtig puls, svimmelhed, sløvhed, rastløshed, hævelse i ansigtet, stramning i halsen, ubehag omkring injektionsstedet.